The value growth of Indian Pharmaceutical Market (IPM) as per the secondary sales audit (SSA) for the month of September 2009 was recorded relatively lower at 9.6 per cent as compared to 16.5 per cent growth in month of August 2009, according to ORG IMS which has announced the Market Reflections for the month of September, 2009 as per their secondary sales audit.

ORG IMS, the world’s leading provider of market intelligence to the pharmaceutical and healthcare industry, also announced that there were no changes observed in the ranking of top ten companies for the month of September 2009. Cipla continued to be at the top spot with Ranbaxy and GSK on second and third position. The remaining positions were occupied by Piramal Healthcare, Zydus Cadila, Sun, Alkem, Lupin, Mankind and Aristo, in that order.

Among the 20 leading companies, the top gainers for the month of September (as compared to August 2009), were sanofi aventis, Emcure and Intas Pharma, who have gained one rank each and moved up to rank 15,16 and 18 respectively.

Coming to products, ORG IMS reflections captured some major movers and shakers in the month of September (as compared to August 09). Phensedyl Cough occupied the topmost position, leaping 8 ranks to move up to top rank, while Corex and Voveran were ranked at second and third. Other top gainers included Augmentin, Cifran and Omez who have gained three ranks each and moved up to rank 5,16 and 21 respectively. Revital, Mox, Human Mixtard and Cardace have gained one rank each and moved up to rank 9,11,12 and 20 respectively.